CN108464981B - 抑制tie2激酶的组合物在制备治疗癌症的药物中的用途 - Google Patents

抑制tie2激酶的组合物在制备治疗癌症的药物中的用途 Download PDF

Info

Publication number
CN108464981B
CN108464981B CN201810436668.9A CN201810436668A CN108464981B CN 108464981 B CN108464981 B CN 108464981B CN 201810436668 A CN201810436668 A CN 201810436668A CN 108464981 B CN108464981 B CN 108464981B
Authority
CN
China
Prior art keywords
composition
formula
another embodiment
combination
comprises administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201810436668.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN108464981A (zh
Inventor
D·L·弗林
M·D·考夫曼
B·史密斯
M·S·鲁道兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deciphera Pharmaceuticals LLC
Original Assignee
Deciphera Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deciphera Pharmaceuticals LLC filed Critical Deciphera Pharmaceuticals LLC
Priority to CN201810436668.9A priority Critical patent/CN108464981B/zh
Publication of CN108464981A publication Critical patent/CN108464981A/zh
Application granted granted Critical
Publication of CN108464981B publication Critical patent/CN108464981B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201810436668.9A 2013-11-07 2013-11-07 抑制tie2激酶的组合物在制备治疗癌症的药物中的用途 Active CN108464981B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810436668.9A CN108464981B (zh) 2013-11-07 2013-11-07 抑制tie2激酶的组合物在制备治疗癌症的药物中的用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201380081931.2A CN105873440B (zh) 2013-11-07 2013-11-07 抑制tie2激酶的组合物在制备治疗癌症的药物中的用途
PCT/US2013/069005 WO2015069266A1 (en) 2013-11-07 2013-11-07 Methods for inhibiting tie2 kinase useful in the treatment of cancer
CN201810436668.9A CN108464981B (zh) 2013-11-07 2013-11-07 抑制tie2激酶的组合物在制备治疗癌症的药物中的用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380081931.2A Division CN105873440B (zh) 2013-11-07 2013-11-07 抑制tie2激酶的组合物在制备治疗癌症的药物中的用途

Publications (2)

Publication Number Publication Date
CN108464981A CN108464981A (zh) 2018-08-31
CN108464981B true CN108464981B (zh) 2022-06-24

Family

ID=53041876

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380081931.2A Active CN105873440B (zh) 2013-11-07 2013-11-07 抑制tie2激酶的组合物在制备治疗癌症的药物中的用途
CN201810436668.9A Active CN108464981B (zh) 2013-11-07 2013-11-07 抑制tie2激酶的组合物在制备治疗癌症的药物中的用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201380081931.2A Active CN105873440B (zh) 2013-11-07 2013-11-07 抑制tie2激酶的组合物在制备治疗癌症的药物中的用途

Country Status (7)

Country Link
EP (1) EP3065549A4 (ko)
JP (1) JP6568093B2 (ko)
KR (2) KR20160070188A (ko)
CN (2) CN105873440B (ko)
AU (3) AU2013404949B2 (ko)
CA (1) CA2929715A1 (ko)
WO (1) WO2015069266A1 (ko)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
KR20160070188A (ko) * 2013-11-07 2016-06-17 데시페라 파마슈티칼스, 엘엘씨. 암치료에 유용한 tie2 키나아제의 억제 방법
ES2710211T3 (es) 2014-02-04 2019-04-23 Pfizer Combinación de un antagonista de PD-1 y un inhibidor de VEGFR para tratar el cáncer
RU2714233C2 (ru) 2015-02-26 2020-02-13 Мерк Патент Гмбх Ингибиторы pd-1 / pd-l1 для лечения рака
WO2016191401A1 (en) * 2015-05-27 2016-12-01 Albert Einstein College Of Medicine, Inc. Tmem active test and uses thereof in diagnosis, prognosis and treatment of tumors
CA2989586A1 (en) 2015-06-16 2016-12-22 Pfizer, Inc. Pd-l1 antagonist combination treatments
CN114191428A (zh) 2016-03-02 2022-03-18 卫材研究发展管理有限公司 基于艾日布林的抗体-药物偶联物和使用方法
US10690673B2 (en) 2016-03-29 2020-06-23 Mayo Foundation For Medical Education And Research Method of treating cancer metastasis by CDK 4/6 inhibitors
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
KR20190062515A (ko) 2016-10-06 2019-06-05 화이자 인코포레이티드 암의 치료를 위한 아벨루맙의 투약 용법
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CN106822128A (zh) * 2017-02-24 2017-06-13 南华大学附属第医院 酪氨酸激酶抑制剂dcc‑2036的新应用
CN111818915B (zh) 2018-01-31 2024-05-24 德西费拉制药有限责任公司 治疗胃肠道间质瘤的组合疗法
CN110003181B (zh) * 2019-05-22 2020-08-28 北京凯恩梅格医药科技有限公司 一种基于克唑替尼结构的c-Met/HDAC双靶点抑制剂及其合成方法与应用
TW202122085A (zh) * 2019-08-12 2021-06-16 美商迪賽孚爾製藥公司 治療血管畸形之方法
KR20220045189A (ko) 2019-08-12 2022-04-12 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양을 치료하는 방법
TW202122082A (zh) 2019-08-12 2021-06-16 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
CN112812109B (zh) * 2019-11-18 2022-06-21 中国科学院微生物研究所 化合物DaP-01及其制备方法和应用
JP2023509628A (ja) 2019-12-30 2023-03-09 デシフェラ・ファーマシューティカルズ，エルエルシー １－（４－ブロモ－５－（１－エチル－７－（メチルアミノ）－２－オキソ－１，２－ジヒドロ－１，６－ナフチリジン－３－イル）－２－フルオロフェニル）－３－フェニル尿素の組成物
EP4327827A3 (en) 2019-12-30 2024-05-29 Deciphera Pharmaceuticals, LLC Amorphous kinase inhibitor formulations and methods of use thereof
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013036232A2 (en) * 2011-09-08 2013-03-14 Deciphera Pharmaceuticals, Llc Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases
WO2013066440A1 (en) * 2011-07-29 2013-05-10 Medivation Prostate Therapeutics, Inc. Treatment of breast cancer
CN105873440B (zh) * 2013-11-07 2018-06-01 德西费拉制药有限责任公司 抑制tie2激酶的组合物在制备治疗癌症的药物中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130023587A1 (en) * 2010-04-01 2013-01-24 Duke University Compositions and methods for the treatment of cancer
WO2011150198A1 (en) * 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl urea compounds and methods of use thereof
WO2012097021A1 (en) * 2011-01-11 2012-07-19 Glaxosmithkline Llc Combination
US20130071403A1 (en) * 2011-09-20 2013-03-21 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013066440A1 (en) * 2011-07-29 2013-05-10 Medivation Prostate Therapeutics, Inc. Treatment of breast cancer
WO2013036232A2 (en) * 2011-09-08 2013-03-14 Deciphera Pharmaceuticals, Llc Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases
CN105873440B (zh) * 2013-11-07 2018-06-01 德西费拉制药有限责任公司 抑制tie2激酶的组合物在制备治疗癌症的药物中的用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Abstract B78: Rebastinib, a small molecule TIE2 kinase inhibitor, prevents primary tumor growth and lung metastasis in the PyMT breast cancer mode";Bryan D. Smith et al.;《Cancer research》;20130228;第73卷;摘要 *
Bryan D. Smith et al.."Abstract B78: Rebastinib, a small molecule TIE2 kinase inhibitor, prevents primary tumor growth and lung metastasis in the PyMT breast cancer mode".《Cancer research》.2013,第73卷摘要. *

Also Published As

Publication number Publication date
AU2019200261A1 (en) 2019-01-31
KR20210063475A (ko) 2021-06-01
AU2013404949B2 (en) 2018-10-18
KR20160070188A (ko) 2016-06-17
WO2015069266A1 (en) 2015-05-14
EP3065549A4 (en) 2017-05-24
CN105873440B (zh) 2018-06-01
JP6568093B2 (ja) 2019-08-28
CN105873440A (zh) 2016-08-17
JP2017500371A (ja) 2017-01-05
CN108464981A (zh) 2018-08-31
AU2013404949A1 (en) 2016-05-26
CA2929715A1 (en) 2015-05-14
EP3065549A1 (en) 2016-09-14
AU2021200113A1 (en) 2021-03-04

Similar Documents

Publication Publication Date Title
CN108464981B (zh) 抑制tie2激酶的组合物在制备治疗癌症的药物中的用途
US20190091217A1 (en) Methods for inhibiting tie-2 kinase useful in the treatment of cancer
CN108024540B (zh) 用于治疗癌症的方法
TW202038957A (zh) 抗體-藥物結合物與激酶抑制劑之組合
KR102320190B1 (ko) 아필리모드 조성물 및 이를 사용하기 위한 방법
US20100297118A1 (en) Therapeutic Cancer Treatments
JP6716585B2 (ja) 結腸直腸癌の処置に使用するためのアピリモド
US11224608B2 (en) Compounds and methods for treating cancer
TW201609094A (zh) 治療癌症之新穎方法
KR20170134462A (ko) Mdm2 저해제와 btk 저해제의 병용 치료법
KR101825637B1 (ko) 암 예방 또는 치료용 약학적 조성물 및 이의 용도
US20220047573A1 (en) Methods for treating vascular malformations
US20130150386A1 (en) Methods for the treatment of lung cancer
KR20180102559A (ko) 암 치료를 위한 아필리모드를 가진 바이오마커
KR101824205B1 (ko) 암 예방 또는 치료용 약학적 조성물 및 이의 용도
JP6945587B2 (ja) ガンの処置に有用なｔｉｅ２キナーゼの阻害方法
KR101828997B1 (ko) 암 예방 또는 치료용 약학적 조성물 및 이의 용도
KR101824197B1 (ko) 암 예방 또는 치료용 약학적 조성물 및 이의 용도
WO2014089570A1 (en) Combinations of a pi3k/akt inhibitor compound with an her3/egfr inhibitor compound and use thereof in the treatment of a hyperproliferative disorder
AU2021200121A1 (en) Pharmaceutical compositions and use thereof for relieving resistance due to cancer chemotherapy and enhancing effect of cancer chemotherapy
WO2021030404A1 (en) Methods and compositions for treating vascular malformations
CN116568326A (zh) 用于治疗实体瘤的方法及包括krasg12c抑制剂和vegf抑制剂的组合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1257617

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant